Investment Considerations
- Proprietary and unique oral drug delivery technology
- Broad patent estate safeguarding intellectual property
- Diverse product pipeline addressing large markets
- Lead programs of oral heparin and insulin complemented by existing collaborations with major pharmaceutical companies